Company: MDXG
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001376339-25-000048
Chunk: 34

Company: MIMEDX GROUP, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 34
---
ii) long-term debt, net.

Company Performance Driven and Measured by Execution Against Strategic Initiatives

In 2024, our management of the business was guided by the following three strategic initiatives, which are designed to drive growth in our business over both the short- and long-term:

<div align='center'>17</div>

• Innovate & Diversify the Product Portfolio to Maximize Growth

• Develop & Deploy Programs to Expand Surgical Footprint

• Enhance Customer Intimacy

We allocate our time and resources into each of these strategic initiatives and assess our performance against measurable goals that advance each initiative.

Our first strategic priority is to continue to innovate and diversify our product portfolio. With over a decade of experience developing and commercializing products that have been widely adopted in several care settings, the Company continues to focus on efforts to lead the industry with new, innovative and differentiated products. As we expand the breadth of our portfolio with highly complementary products, such as our most recent expansion into xenografts with HELIOGEN™, we believe we can offer a best-in-class range of products to support physicians in achieving wound healing for their patients. Additionally, the Company also added CELERA™ to our product offering late in the year to expand our product offering for the private physician office and associated care settings.

Our second priority is to develop and deploy programs intended to expand our footprint in the surgical market. Our products are used in a variety of surgical settings, and our strategic goals include building a body of evidence and real-world use data for our products in a wide range of procedures. The most common applications in surgical procedures include the use of our allografts in the closure of acute wounds, as well as the use of our allografts inside the body to protect or reinforce tissues and/or regions of interest. The associated market potential for our product portfolio in these surgical procedures represents a sizable opportunity for the Company, and we are well underway in working with collaborators to generate clinical evidence and scientific research to support our growth in this market.

Our third initiative is to introduce programs designed to enhance customer intimacy. The purpose of this initiative is to help improve our customer relationships, translating to lower customer turnover. We have undertaken a variety of measures in support of this initiative, most notably with the 2024 launch of MIMEDX Connect™ . The adoption of this first-of-its-kind solution has continued to ramp up, with more than 1,000 customers using the platform to perform functions such as insurance verification and product ordering